Glycomine Completes Enrollment in Global Phase 2b POLAR Study of GLM101 for the Treatment of PMM2-CDGMay 13, 2026Read article
Aura Biosciences Reports First Quarter 2026 Financial Results and Business HighlightsMay 13, 2026Read article
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesMay 13, 2026Read article
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded WarrantsMay 13, 2026Read article
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsMay 13, 2026Read article
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment CompletionMay 13, 2026Read article
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsMay 13, 2026Read article
Aura Biosciences Reports Third Quarter 2025 Financial Results and Business HighlightsDecember 15, 2025Read article
Aura Biosciences to Participate in the 8th Annual Evercore Healthcare ConferenceDecember 15, 2025Read article
Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceNovember 7, 2025Read article
